Shiba Inu (SHIB) futures contracts saw $257.4 million traded in 24 hours, over three times the $77.5 million on the spot market, highlighting futures as the main driver of SHIB price movements. Open interest in SHIB futures stood at $169 million, indicating significant leverage exposure. European regulations, particularly from ESMA and BaFin, limit retail investors to 2:1 leverage on crypto contracts for difference, aiming to reduce risk. Investors should consider leverage limits, tax differences, and custody implications when trading SHIB futures versus spot tokens.
Shiba Inu futures trading volume reached $257.4 million in 24 hours, more than triple the $77.5 million on the spot market, with open interest at $169 million as of Oct 16, 2026 01:02 WIB. For readers following cryptocurrency markets, here is Pluang's snapshot: out of 50 major cryptocurrencies priced, 25 rose and 24 fell today. Notable movers include CRV at Rp6.481 (+8.69%, typical hold time 62 days, 98% buy orders), EOS at Rp12.649 (+8.13%, typical hold time 87 days), and XTZ at Rp5.785 (+4.74%, typical hold time 100 days, 77% sell orders).
Citigroup increased its price target for Krystal Biotech to $416 from $386, citing strong Q2 revenue of $119.2 million from its approved product Vyjuvek and encouraging early clinical data for KB113, a treatment for basal cell carcinomas in Gorlin sy...
Bank7 Corp. reported Q3 2026 earnings of $1.06 per share, slightly beating analyst estimates, while revenue of $23.37 million fell short and declined year-over-year. Despite lower revenue and earnings compared to last year, the bank continues to grow...
Scotiabank increased its price target for Targa Resources to $319 from $314, indicating a potential 12.7% upside from the current share price of around $283. Targa Resources, a key player in the midstream energy sector, is recognized as a top momentu...
Ericsson reported better-than-expected Q3 earnings with EPS of $0.18 and revenue of $5.91 billion, driven by strong demand in its mobile network segment. The Networks division showed 9% organic growth and a gross margin above guidance, but overall op...
The obesity treatment landscape is rapidly evolving with over 200 companies developing more than 200 pipeline drugs, including late-stage and early-stage clinical trials. Major pharmaceutical firms like Novo Nordisk and Eli Lilly are leading with inn...
